Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

Cell death escape is one of the most prominent features of tumor cells and closely linked to
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …

To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute
myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene …

Suppression of apoptosis by expression of antiapoptotic BCL2 family members is a hallmark
of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein …

Mitochondrial apoptosis can be effectively targeted in lymphoid malignancies with the FDA-
approved B cell lymphoma 2 (BCL-2) inhibitor venetoclax, but resistance to this agent is …

While the understanding of the genomic aberrations that underpin chronic and acute
myeloid leukaemia (CML and AML) has allowed the development of therapies for these …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

The approval of venetoclax, a 'BH3-mimetic'antagonist of the BCL-2 anti-apoptotic protein,
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …

FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …